Revenue - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details) - USD ($) $ in Millions		12 Months Ended
	Dec. 21, 2021	Dec. 31, 2023
Transaction price
Deferred revenues as of December 21, 2021	$ 165
Option payment for Domvanalimab	275
Option payment for Etrumadenant	250
Option payment for Quemliclustat	200
Total transaction price	890
Allocation to performance obligations
Domvanalimab - License	329
Domvanalimab - R&D services	34
Etrumadenant - License and R&D services	219
Quemliclustat - License and R&D services	176
Zimberelimab - R&D and commercial services	11
Access rights	84
Option continuation periods	37
Total allocated transaction price	$ 890	$ 35
Inflammation target 1 - R&D services
Allocation to performance obligations
Total allocated transaction price		18
Inflammation target 2 - R&D services
Allocation to performance obligations
Total allocated transaction price		$ 17